



It's a Done Deal

\$8,512,500



Follow-On

Sole Placement Agent

JUNE 2023

ROTH MKM Acted as Sole Placement Agent Panbela Therapeutics, Inc. (Nasdaq: PBLA) in its \$8.5 Million Follow-On

**For more information
please contact:**

Investment Banking

James Antonopoulos

Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906

jantonopoulos@roth.com

Aparna Beeram

Senior Vice President
Investment Banking
(646) 358-1912

abeeram@roth.com

Equity Capital Markets

Aaron Gurewitz

President & Head of
Investment Banking
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz

Transaction Information

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the "Public Warrants") at a purchase price of \$3.75 per share and associated Public Warrants. The Public Warrants will have an exercise price of \$3.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about June 21, 2023.

ROTH MKM acted as sole placement agent for the offering.

About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela's lead assets are Ivospemin (SBP-101) and Flynpovi. For further information about the Company, please

COO &
Managing Director
Equity Capital Markets
(949) 720-5740
nakdeniz@roth.com

Lou Ellis
Managing Director
Equity Capital Markets
(949) 720-5739
lellis@roth.com

visit www.Panbela.com (Source: Company Website 6.16.23)

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 6.23.23

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2023.

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com

